Rabeprazole + Amoxicillin + Clarithromycin

The combination of rabeprazole, amoxicillin, and clarithromycin (often abbreviated as RAC) is a triple therapy regimen primarily used for the eradication of Helicobacter pylori (H. pylori) infection, which is associated with peptic ulcers and other gastrointestinal conditions. ## Composition and Mechanism This triple therapy combines three distinct medications: 1. **Rabeprazole**: A proton pump inhibitor (PPI) that decreases stomach acid production by inhibiting the gastric H+,K+ ATPase enzyme (proton pump) at the secretory surface of gastric parietal cells[3][5]. 2. **Amoxicillin**: A bactericidal antibiotic similar to penicillin that inhibits cell wall biosynthesis in susceptible bacteria during active multiplication, leading to bacterial death[2]. 3. **Clarithromycin**: A macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome and preventing translocation[2][6]. ## Clinical Efficacy Studies have shown this combination to be highly effective for H. pylori eradication: - A standard 7-day regimen has demonstrated an average eradication rate of 87.2%[1]. - Some studies have found that a 7-day regimen is just as effective as a 10-day regimen, with no significant advantage to the longer duration[1]. - A pilot study of a shortened 4-day triple therapy with this combination achieved a 90% eradication rate, comparable to established 7-day regimens[8]. ## Administration The typical administration is twice daily for 7 days, though in cases of severity, treatment may be extended to 14 days[2]. The medications are often packaged together in dosing cards to facilitate proper administration. ## Side Effects Adverse reactions reported with this combination therapy include: - Digestive system: Nausea, vomiting, diarrhea, dark stools, dry mouth, glossitis, oral moniliasis, stomatitis, tongue discoloration[2][5]. - Nervous system: Confusion, headache, dizziness[2]. - Musculoskeletal system: Myalgia[2]. - Skin reactions[2]. - Urogenital system: Vaginitis, vaginal moniliasis[2]. In clinical trials, the most frequently reported drug-related adverse reactions for patients receiving this therapy for 7 or 10 days were diarrhea (8% and 7%) and taste perversion (6% and 10%), respectively[5]. ## Indications This combination is specifically indicated for: - Eradication of H. pylori in active chronic gastric and duodenal ulcers[2]. - Treatment and prevention of ulcers associated with H. pylori infection[3]. ## Contraindications The therapy is contraindicated in patients with known hypersensitivity to any of its components[2]. Special care should be taken when administering to elderly patients who may suffer from asymptomatic renal and hepatic dysfunction[2]. ## Drug Interactions Clarithromycin may interact with several medications including theophylline, carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfetanil, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, cisapride, pimozide, and astemizole[2][5]. This triple therapy has proven to be a valuable first-line treatment option for H. pylori infection, with high efficacy rates and a manageable side effect profile.

Brand names

RabecurePylocure

Other names

Triple therapy regimen